Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

NCT05842018 ↗

Phase 2 Unknown 30 enrolled Tianjin Medical University Cancer Institute and Hospital

NaSingle-groupOpen-labelTreatment

Summary

This is a phase II, single arm, open-label, single-center study to evaluate the efficacy and safety of Toripalimab combined with Chemotherapy and Antiangiogenic Agents in patients with Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 inhibitors)

Timeline

Start: 2023-05-01
Primary completion: 2025-05-01
Completion: 2025-11-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	12 mg	—
Subject	Toripalimab	Monoclonal antibody	240 mg	Intravenous
Background	Gemcitabine	Small molecule	—	—
Background	Paclitaxel	Small molecule	—	—
Background	Pemetrexed	Small molecule	—	—

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Summary

Timeline

Drugs

Indications